Choosing the Right Crystal: Solid Form Optimization for Pharmaceutical Development

Chemical entities can be packed in different three-dimensional arrangements through various intermolecular interactions, resulting in multiple crystalline forms with distinct properties. In pharmaceutical development, these solid forms can directly influence drug performance and intellectual property strategy, making solid-state selection a critical consideration in early-stage development.

When key properties of the API such as dissolution, stability, or processability do not meet development requirements, solid form optimization, including polymorph screening, salt formation, and cocrystallization, can be applied without changing the chemical structure of the compound. Different crystal forms of the same API may also exhibit distinct properties that enable separate patent protection, making crystal form patents an important element of intellectual property strategy.

Overall, a comprehensive understanding of solid form landscape is essential in pharmaceutical development. On June 10, our Formulation expert, Dr. Zi Li, will present key aspects of crystalline forms in drug development, share case studies on how solid form optimization can modify drug properties, and discuss preformulation strategies to accelerate preclinical formulation workflows.

What you will learn:

Key concepts and practical applications of polymorphs, salts, and cocrystals

How solid form optimization is used in practice to modulate and improve drug properties

How preformulation studies support early-stage formulation development and decision-making

Register Now

Speakers:

Zi Li, Ph.D.

Associate Director, Formulation

BioDuro